Here are 1-3 brief analogies for Stereotaxis (STXS):

• Intuitive Surgical for heart catheter procedures.
• Garmin for guiding medical devices inside the human body with robotic precision.

Here are the major products of Stereotaxis (STXS):

• Genesis RMN and Niobe Systems: Robotic magnetic navigation (RMN) systems that enable image-guided delivery of catheters and guidewires for complex interventional procedures.
• Odyssey: A real-time information solution designed to manage, control, record, and share interventional procedures across networks.
• Stereotaxis Imaging Model S X-ray System: A comprehensive single-plane X-ray system for robotic interventional operating rooms, including a c-arm, powered table, and high-definition monitors.
• Electrophysiology Catheters and Disposables: This category includes QuikCAS automated catheter advancement disposables and various steerable tip diagnostic/ablation catheters such as the CARTO RMT, CELSIUS RMT, and NAVISTAR RMT series.
• Vdrive System: A system providing navigation and stability for diagnostic and therapeutic devices, complemented by disposable components like V-Loop, V-Sono, and V-CAS.
• Magnetic Ablation Catheter (in development): A magnetic ablation catheter being developed in collaboration with Osypka AG, leveraging Stereotaxis' robotic technology.

• Johnson & Johnson (JNJ)
• TTM Technologies, Inc. (TTM)
• Osypka AG

David L. Fischel, Chairman and Chief Executive Officer

David Fischel became a Director of Stereotaxis in September 2016, and assumed the roles of CEO and Chairman in February 2017. Prior to joining Stereotaxis, he spent over eight years as a Principal and portfolio manager, focusing on medical device investments at DAFNA Capital Management, LLC. Before DAFNA Capital, he worked as a research analyst at SCP Vitalife, a healthcare venture capital fund. Mr. Fischel holds a B.S. magna cum laude in Applied Mathematics from UCLA and an MBA from Bar-Ilan University. He is also a Certified Public Accountant (CPA), Chartered Financial Analyst (CFA), and Chartered Alternative Investment Analyst (CAIA). His career includes a transition from an investor to an operator within the medical device space.

Kimberly Peery, Chief Financial Officer

Kimberly Peery was appointed Chief Financial Officer of Stereotaxis, effective October 1, 2019. She initially joined the company in 2003 and previously held the position of Vice President of Finance. Before her tenure at Stereotaxis, Ms. Peery gained experience as a controller at various private companies. She is a Certified Public Accountant and earned both a Bachelor of Science in Accounting and a Master of Science in Accounting and Computer Science from Southern Illinois University, Edwardsville.

Patricia Williams, General Counsel

Patricia Williams joined Stereotaxis in 2025. She brings over two decades of legal experience from significant healthcare and publicly traded companies, including roles at Peabody Energy (NYSE: BTU), the integrated healthcare system SSM Health, RehabCare Group (acquired by Kindred Healthcare), and Thermadyne Holdings (NSDQ: THC).

Keith Galloway, Vice President of Operations

Keith Galloway became part of the Stereotaxis team in 2010 and was promoted to Vice President of Operations in September 2019. He has more than 15 years of experience, specializing in strategy and financial analytics. Prior to Stereotaxis, he completed an Executive Development Program and worked as a Senior Financial Analyst at Anheuser Busch/InBev. Mr. Galloway is a CFA Charterholder and holds a bachelor's degree in Mechanical Engineering and an MBA in Finance and Marketing from Washington University in St. Louis.

Casey Payne, Vice President, APAC Sales & Global Training

Casey Payne leads Stereotaxis' commercial teams in the Asia Pacific region and also oversees Global Training. Before joining Stereotaxis, he held commercial positions at Genentech. Mr. Payne earned his B.S. in Systems Engineering from the United States Military Academy at West Point and an MBA from the University of North Carolina at Chapel Hill.

1. Financial Health and Cash Burn

   Stereotaxis faces significant financial challenges, including poor financial strength ratings, high debt levels, and persistent operating losses that lead to a high cash burn rate. The company's balance sheet has been described as weak, with limited cash reserves and a short cash runway, necessitating potential future capital raises that could dilute existing shareholders. Some analyses have placed the company in a "distress zone," indicating a potential risk to its continued operations.

2. Regulatory Delays and Commercial Adoption

   The company's ability to grow revenue and achieve profitability is highly dependent on timely regulatory approvals for its new products, such as Genesis X and MAGiC catheters. Delays in obtaining these approvals can significantly push back commercialization timelines. Furthermore, even with approvals, the adoption of Stereotaxis's robotic systems and disposables by hospitals faces hurdles due to lengthy purchasing cycles, the substantial capital expenditure required, and the need for clear demonstrations of clinical and cost benefits.

3. Competitive Landscape and Market Acceptance of Robotic Navigation

   While Stereotaxis is a pioneer and leader in robotic magnetic navigation, it operates within a broader medical device industry, particularly the electrophysiology market, that is dominated by larger, established companies. The company faces ongoing competition from new robotic platforms and improved manual catheter offerings from these major players. The long-term success of Stereotaxis's business also hinges on the broader market acceptance and increased utilization of robotic magnetic navigation in interventional procedures.

• Robotic Magnetic Navigation (RMN) Systems: The global Robotic Magnetic Navigation (RMN) System market is projected to reach an estimated $518 million by 2025, with an anticipated expansion to between $500 million and $700 million by the end of the forecast period (within 5-7 years from 2025).
• Electrophysiology (EP) Ablation Market (including ablation catheters and related systems/disposables): The global electrophysiology ablation market was valued at USD 7.17 billion in 2025 and is projected to grow to approximately USD 21.86 billion by 2035. More specifically, the global electrophysiology ablation catheters market was valued at $4.11 billion in 2025 and is expected to reach $7.83 billion by 2029. Another perspective on this segment, the global cardiac ablation market, was valued at USD 5.8 billion in 2025 and is projected to grow to USD 20 billion by 2035.
• Stereotaxis Imaging Model S X-ray System: The global Stereotactic X-Ray Market, which includes such systems, is projected to reach USD 2.1 billion by 2030, increasing from USD 1.4 billion in 2024.

Stereotaxis (STXS) is poised for future revenue growth over the next two to three years, driven by the increasing adoption of its robotic systems, the expansion of its disposable catheter portfolio, the introduction of new technologies, and strategic market initiatives.

Here are 3-5 expected drivers of future revenue growth for Stereotaxis:

1. Increasing Adoption and Global Expansion of Genesis RMN and GenesisX Robotic Systems: Stereotaxis expects continued double-digit revenue growth in 2026, supported by increased production capabilities and commercial adoption of its Genesis RMN and the next-generation GenesisX robotic systems. The GenesisX system, which offers enhanced accessibility due to smaller magnets and integrated magnetic shielding, has already secured its first order and received regulatory approvals in the United States, Europe, and China, indicating significant potential for broader market penetration. Furthermore, successful initial procedures with the Genesis RMN system in prominent cardiac centers, such as Erasmus University Medical Center in the Netherlands and Corewell Health in Michigan, are fostering clinical confidence and encouraging wider adoption globally.
2. Growth in Recurring Revenue from Disposable Catheters, Particularly the MAGiC Line: A significant portion of Stereotaxis's revenue growth is anticipated from its recurring streams, primarily driven by the sales of disposable catheters, especially the MAGiC ablation catheter line. The MAGiC ablation catheter has received CE Mark approval in Europe and regulatory approvals in the U.S. and Europe for MAGiC and MAGiC Sweep high-density mapping catheter, paving the way for broad adoption among robotic users. Clinical experience with MAGiC in ongoing European studies further supports expectations for its increased utilization, contributing substantially to recurring revenue.
3. Introduction of Innovative New Products and Technologies: Stereotaxis is expanding its product portfolio with advanced technologies designed to enhance interventional procedures. The company plans to launch MAGiC with Pulse Field Ablation in Europe by the end of 2025, which is expected to boost revenue potential through new product marketing. Additionally, Stereotaxis is investing in its Synchrony digital surgery suite technology, with anticipated FDA clearance and projected revenue exceeding $3 million from initial demand in 2026, further diversifying its revenue streams.
4. Strategic Collaborations and Evolving Commercial Models: Strategic partnerships and a refined commercial approach are expected to drive revenue growth. The ongoing collaboration with Osypka AG for the development and manufacturing of a next-generation magnetic ablation catheter, fully owned by Stereotaxis, underpins the company's proprietary catheter offerings. The successful integration of Abbott's EnSite X EP System with Stereotaxis's Robotic Magnetic Navigation System also represents a significant step, combining advanced cardiac mapping with robotic precision to improve arrhythmia treatment, potentially increasing the adoption of Stereotaxis's technology in electrophysiology labs. Moreover, Stereotaxis is transitioning to a more attractive commercial model, blending sales, leases, and placements funded by disposable commitments, which is designed to enhance revenue potential and encourage broader adoption by healthcare providers.

Share Issuance

• Stereotaxis has experienced a consistent increase in its shares outstanding over the last three to five years, rising from approximately 73 million in Q4 2020 to 92 million in Q4 2025.
• The company's shares outstanding increased from 75.8 million in 2021 to 92.01 million in 2025.
• Stereotaxis has a Sales Agreement with Roth Capital Partners, LLC, facilitating at-the-market offerings of common stock under an effective shelf registration statement on Form S-3.

Capital Expenditures

• Capital expenditures for Stereotaxis totaled -$93,000 in the last 12 months reported as of March 15, 2026.
• In the third quarter of 2025, capital expenditures were $0.000 million, marking a 100% decrease from the previous quarter.